GPT and steatosis: Regarding the transaminase levels, secondary to the SGLT-2i treatment of patients with T2DM, their amelioration is the last part of the process that starts with a reduction in body weight, a decrease in liver fat content with a secondary amelioration of steatosis, and a reduction in GOT and GPT levels [46].